Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. - Neal JW; Santoro A; Gonzalez-Cao M; Lim FL; Fang B; Gentzler RD; Goldschmidt J; Khrizman P; Proto C; Patel S; Puri S; Liu SV; et al. (JTO clinical and research reports, 2024)